• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

The Weekly Roundup: June 2-6

Key Takeaways

  • REX-8756, an oral STAT6 inhibitor, shows potential for safer treatment of type 2 inflammatory skin diseases, including atopic dermatitis.
  • Atopic dermatitis is associated with a higher risk of dementia, as identified through a comprehensive review and meta-analysis.
SHOW MORE

In case you missed it, this week we had news about denifanstat's promising phase 3 results for acne, emerging therapies in lichen planus, initial insights from RAD 2025, and more.

dermatology times weekly roundup graphic

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Dermatology Conferences and Meetings Calendar: June 2025

Dermatology Times has compiled a list of dermatological meetings taking place during the month of June.

Recludix Pharma Advances First-in-Class Oral STAT6 Inhibitor REX-8756 for Inflammatory Diseases, Including Atopic Dermatitis

Recludix advances REX-8756, a first-in-class oral STAT6 inhibitor, showing promise for safer, targeted treatment of type 2 inflammatory skin diseases.

Adam Friedman, MD, FAAD: Spotlighting Disparities in Lichen Planus Screening and Treatment

Friedman discusses survey findings revealing inconsistent screening, outdated assumptions, and lack of FDA-approved therapies for lichen planus.

Atopic Dermatitis Associated With Higher Dementia Risk

Through a comprehensive review and meta-analysis, researchers identified the correlation between atopic dermatitis and dementia.

Arcutis’ Roflumilast Becomes First FDA-Approved Treatment to Receive the NPF’s Seal of Recognition

The National Psoriasis Foundation Seal of Recognition program has expanded to prescription drugs, making roflumilast the first to achieve the indication.

Road to RAD: The Ins and Outs of Managing CHE

Jonathan Silverberg, MD, PhD, MPH, shares his insights on treating and managing CHE.

Visible Light Protection: Needs and Strategies for Diverse Patients

New research highlights the importance of tinted sunscreens with iron oxides for effective protection against visible light-induced skin pigmentation, especially for darker skin tones.

Journal Digest: June 4, 2025

This review of the latest dermatologic studies includes insights into clinical manifestations of mpox infection, therapeutic modulation of Demodex density via isotretinoin, and more.

Denifanstat Hits All Targets in Chinese Study

Sagimet Biosciences reveals denifanstat's promising phase 3 results, offering a novel oral treatment for moderate to severe acne with significant efficacy.

Bridging the Gaps in Lichen Planus Treatment: Emerging Therapies and Clinical Realities

In part 2 of this conversation, Adam Friedman, MD, FAAD, discusses new data on lichen planus treatment trends, unmet needs, and the promise of innovative therapies.

Examining the Halfway Mark of 2025 in Dermatology

Discover the latest advancements in dermatology in our June issue, including FDA approvals, innovative treatments, and expert insights shaping patient care today.

Road to RAD: What’s Next in the AD Pipeline?

Jonathan Silverberg, MD, PhD, MPH, walks through what to look out for in AD management.

Time in the Market: What History Tells Us About Investing During Volatile Markets

Market pullbacks tempt investors to time the market, but history shows staying invested beats guessing the highs and lows—time > timing.

Calling for Collective Investment and Action in Lichen Planus Care

In part 3 of this conversation, Adam Friedman, MD, FAAD, discusses the need for unity in advancing lichen planus care and research.

The Growing Burden of Acne in America: Time to Rethink Our Approach

Acne is increasingly recognized as a chronic condition, affecting diverse populations and demanding innovative treatment strategies and equitable care access.

Targeted TYK2 Blockade for PsO Without JAK1/2/3 Impact

Zasocitinib emerges as a promising oral therapy for psoriasis and psoriatic arthritis, showcasing superior selectivity and safety compared to traditional JAK inhibitors.

Tristan Hasbargen, PA-C, Builds Surgical Skills and Support at Fall Clinical PA/NP

Tristan Hasbargen, PA-C, led a hands-on suturing workshop at the Fall Clinical NP/PA Conference, enhancing skills in surgical dermatology.

Novel OS-01 Peptide Body Lotion Reduces Inflammation and Strengthens Skin Barrier

The OS-01 peptide formulation enhanced skin barrier function and reduced inflammation, showing promising results in a 12-week clinical trial.

Previewing the 2025 Revolutionizing Atopic Dermatitis Conference

Catch up on what to expect at this year's RAD conference in Nashville, Tennessee.

Road to RAD: Dermatology Times Board Member Presenters

Discover the latest breakthroughs in atopic dermatitis treatment and expert insights from the RAD dermatology conference in Nashville.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.